Spots Global Cancer Trial Database for duke
Every month we try and update this database with for duke cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma | NCT00979173 | Glioma | AC480 | 18 Years - | Duke University | |
| AMG 102 and Avastin for Recurrent Malignant Glioma | NCT01113398 | Glioblastoma Mu... Gliosarcoma | AMG 102 Avastin | 18 Years - | Duke University | |
| Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | NCT01989052 | Malignant Gliom... | CTO Lomustine | 18 Years - | Duke University | |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | NCT01450826 | Nausea Vomiting Glioma | aprepitant ondansetron | 18 Years - | Duke University | |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | NCT00920868 | Solid Tumor Metastatic Colo... | dasatinib bevacizumab Oxaliplatin Capecitabine | 18 Years - | Duke University | |
| Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | NCT01954030 | Malignant Gliom... | CTO and Bevaciz... CTO alone | 18 Years - | Duke University | |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | NCT00920868 | Solid Tumor Metastatic Colo... | dasatinib bevacizumab Oxaliplatin Capecitabine | 18 Years - | Duke University | |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | NCT04547777 | Glioma, Maligna... | D2C7-IT 2141-V11 | 18 Years - | Duke University | |
| Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | NCT00979017 | Glioblastoma Mu... Gliosarcoma | Avastin Temozolomide Irinotecan | 18 Years - | Duke University | |
| Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT01186406 | Glioblastoma Mu... Gliosarcoma | Gliadel Radiation Thera... Avastin Temodar | 18 Years - | Duke University | |
| ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM | NCT05283109 | Glioma, Maligna... | Tumor Associate... Hiltonol | 18 Years - | Duke University | |
| GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM | NCT05695976 | Glioblastoma Glioma, Maligna... | 18 Years - | Duke University | ||
| Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT01186406 | Glioblastoma Mu... Gliosarcoma | Gliadel Radiation Thera... Avastin Temodar | 18 Years - | Duke University | |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | NCT01450826 | Nausea Vomiting Glioma | aprepitant ondansetron | 18 Years - | Duke University | |
| A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 | NCT01061788 | Advanced Solid ... | AMG 479, Everol... | 18 Years - 90 Years | Duke University | |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | NCT04547777 | Glioma, Maligna... | D2C7-IT 2141-V11 | 18 Years - | Duke University | |
| Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | NCT03973879 | Malignant Gliom... | PVSRIPO Atezolizumab | 18 Years - | Duke University | |
| Panitumumab and Irinotecan for Malignant Gliomas | NCT01017653 | Malignant Gliom... | Irinotecan Panitumumab | 18 Years - | Duke University | |
| Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | NCT01954030 | Malignant Gliom... | CTO and Bevaciz... CTO alone | 18 Years - | Duke University | |
| Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma | NCT00979173 | Glioma | AC480 | 18 Years - | Duke University | |
| Lerapolturev (PVSRIPO) in GBM | NCT06177964 | Recurrent Supra... | Lerapolturev Lomustine Pill | 18 Years - | Duke University | |
| PVSRIPO in Recurrent Malignant Glioma | NCT02986178 | Malignant Gliom... | PVSRIPO | 18 Years - | Istari Oncology, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
